Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Table 1
Characteristics of patients before the introduction of olaparib (n = 69).
n (%)
Age at diagnosis (years), median (IQR)
53 (48–59)
ECOG performance status at diagnosis
0
53 (77)
1
16 (23)
Primary tumor location
Ovarian
49 (71)
Fallopian tube
15 (22)
Peritoneal
5 (7)
Histological type
Serous
66 (96)
Endometrial
2 (3)
Mucinous
1 (1)
Gradus III
65 (94)
FIGO stage at diagnosis
I
4 (6)
II
16 (23)
III
38 (55)
IV
10 (15)
Unknown
1 (1)
BRCA mutation type
BRCA 1
56 (81)
BRCA 2
13 (19)
Both
0 (0)
Testing for BRCA
Tumor
23 (34)
Blood
44 (65)
Both
1 (1)
Comorbidities
28 (41)
Residual disease after primary surgery
No macroscopic disease
27 (39)
Macroscopic disease
33 (48)
Unknown
9 (13)
Ascites
No
35 (51)
Yes
26 (38)
Unknown
8 (12)
Data are presented as number (percentage) of patients if not stated otherwise. IQR = interquartile range. Data were missing for BRCA testing for 1 (1%) patient.